Tiziana Life Sciences is trading at $1.02 (+5.15%) in pre-market, extending a technical rebound and dip-buying trend that began in late July.
- The move appears to be a continuation of the recovery seen on July 30, when the stock closed at $0.97 after a 1.17% gain, despite a lack of fresh company-specific news.
- Broader risk-on sentiment in the pre-market session is likely providing additional support for small-cap biotech stocks, contributing to the upward momentum.